There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more research is needed.

With political action underway through an executive order from President Donald Trump and pharmaceutical industry shifts emerging, the question remains whether these changes will lead to sustained ...

The health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...

As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.

GLP-1 weight-loss drugs are reshaping dairy demand by curbing cravings for processed, fatty, and sugary products, fueling a ...

The latest budget proposal to cut anti-obesity medication (AOM) coverage by Medi-Cal will cost the state more in the long run ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states were covering GLP-1s for the treatment of obesity for Medicaid beneficiaries ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

Unless you are from another planet, you’ve heard all about the new weight loss medications taking the world by storm. These ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN ...

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...